Yongping Xie

A general strategy for creating "inactive-conformation" abl inhibitors.

Taebo Sim, Yi Liu, Yongping Xie, 2006, Chemistry & biology.

The alkyl peroxyl radicals and their anions: Structures and electron affinities

Yongping Xie, Xun Sun, Xiao-Ming Fang, 2008 .

A general strategy for creating

M. Warmuth, N. Gray, G. Spraggon, 2006 .

Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.

J. Wityak, E. Saez, R. Epple, 2010, Journal of medicinal chemistry.

Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases

F. Supek, D. Caridha, Yen-Liang Chen, 2020, Journal of medicinal chemistry.

A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.

Taebo Sim, Yongping Xie, Nathanael S Gray, 2010, Journal of medicinal chemistry.

Efficient reversed-phase purification of a hydrophobic reaction product following Mitsunobu-mediated glycosylation.

D. Zembower, Kevin M. Schilling, Yongping Xie, 2002, Journal of chromatography. A.

3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists. Part 2.

J. Wityak, A. Kreusch, E. Saez, 2006, Bioorganic & medicinal chemistry letters.